SearchContact usGeneral Inquiries Greater Montréal Area Greater Quebec Area Sherbrooke and Eastern
|
 BiopolisQuébec Directory
|
3201 Jean-Mignault |
 |
Type of Organization Contract Research Organization Field of Activity
Preclinical Research Therapeutic Applications
Services |
|
|
|
|
|
Corporate Overview
IPS Therapeutique is a specialty Contract Research Organization, fonded in 1999, which dedicates its expertise and technology to the evaluation of the cardiac safety of new drugs at an early stage of their development, by using validated and highly predictive models. Recognized for the quality and the on-time delivery of its IND enabling studies, IPS Therapeutique addresses the particular needs of start-up and mature biopharmaceutical companies which are looking for fast and cost-effective solutions to assess the QT Prolongation and the arrhythmogenic liability of their new compound(s) during preclinical development.
Products / Services :
IPS Therapeutique primarily intends to provide drug developers with regulatory safety prerequisites needed to move to clinical testing, but also to offer biopharmaceutical decision-makers rapid and cost effective solutions to improve the outcome of their drug development programs. Each line of services regroups cardiotoxicity assays which incrementally focus on specific issues or mechanisms that need to be investigated, using different or complementary approaches adapted to a specific compound.
Safe Lead SelectTM... choose your safest lead candidate(s) earlier and with more confidence to cut on development costs.
IND-EnablerTM... to ensure a prompt and seamless IND approval by regulatory authorities.
Torsades PredictTM... beyond regulatory requirements, and into the mechanisms of QT Prolongation.
Human Cardiac Efficacy models... to support and/or validate your cardiovascular efficacy data.
Keywords
Click a keyword to search similar items in the database
contract research organization, cardiac safety, new drugs, early stage, ind enabling studies, qt prolongation, arrhythmogenic liability, preclinical development, safety, clinical testing, cardiotoxicity assays, regulatory authorities, human cardiac efficacy models ,
Location
Highest proportion of R&D employment in Canada*
*fDI Intelligence
